Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Merck-Gilead's weekly HIV combo maintains viral suppression
Early results show that a weekly combo of Merck’s islatravir and Gilead’s Sunlenca maintained a high rate of viral suppression in HIV patients.
Annalee Armstrong
Mar 6, 2024 11:08am
CytoDyn finally clears FDA hold on HIV program after 2 years
Feb 29, 2024 10:20am
HIV protein inhibited by Rukobia linked to cardio comorbidities
Nov 30, 2023 9:30am
HIV drug hydrogel extends treatment longevity to 6 weeks
Sep 25, 2023 2:00pm
HIV gene therapy biotech takes SPAC street
Aug 10, 2023 11:13am
Dual CRISPR therapy for HIV eliminates virus in mice
May 1, 2023 4:35pm